An Analysis of the Anti-Neuropathic Effects of Qi She Pill Based on Network Pharmacology

Table 5

The pathways for QSP in the treatment of NP target (FDR < 0.05).

Name	Term	Count	Genes	P value	FDR
hsa04080	Neuroactive ligand-receptor interaction	32	OPRM1, DRD1, TRPV1, ADORA2A, DRD2, DRD5, OPRK1, ADORA1, HRH1, HTR1A, GRIN2B, HRH2, ADRA2A, ADRA2C, ADRA2B, GABRD, GABRA2, GABRG3, ADRB2, CHRM5, ADRB1, CHRM4, CHRM3, CHRM2, HTR7, CHRM1, ADRA1B, ADRA1A, HTR2C, ADRA1D, HTR2A, OPRD1	1.05E − 34	1.18E − 31
hsa04020	Calcium signaling pathway	19	DRD1, ADORA2A, DRD5, CHRM5, HRH1, ADRB2, ADRB1, CHRM3, HRH2, CHRM2, CHRM1, HTR7, ADRA1B, ADRA1A, HTR2C, ADRA1D, CACNA1A, HTR2A, CACNA1B	4.24E − 18	4.77E − 15
hsa04726	Serotonergic synapse	10	HTR1A, PTGS2, HTR7, SLC6A4, PTGS1, MAOB, HTR2C, CACNA1A, HTR2A, CACNA1B	1.91E − 08	2.14E − 05
hsa04024	cAMP signaling pathway	11	DRD1, ADRB2, HTR1A, ADRB1, GRIN2B, ADORA2A, DRD2, CHRM2, DRD5, CHRM1, ADORA1	2.61E − 07	2.93E − 04
hsa04022	cGMP-PKG signaling pathway	10	ADRB2, ADRB1, ADRA2A, ADRA1B, ADRA1A, ADRA2C, ADRA2B, ADORA1, ADRA1D, OPRD1	4.09E − 07	4.60E − 04
hsa04728	Dopaminergic synapse	9	DRD1, SCN1A, GRIN2B, DRD2, SLC6A3, DRD5, MAOB, CACNA1A, CACNA1B	9.69E − 07	0.001089
hsa05032	Morphine addiction	8	OPRM1, GABRD, DRD1, GABRA2, GABRG3, ADORA1, CACNA1A, CACNA1B	1.23E − 06	0.001381
hsa05033	Nicotine addiction	6	GABRD, GABRA2, GABRG3, GRIN2B, CACNA1A, CACNA1B	4.20E − 06	0.004726